Search - tctmd.com

Displaying 381 - 400 of 629

Sort: Relevancy | Date

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

October 03, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

September 30, 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

September 29, 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

News Conference News TCT 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

September 28, 2019

Surgical Volume Matters When It Comes to Repair of Primary MR

News Conference News TCT 2019

Surgical Volume Matters When It Comes to Repair of Primary MR

September 28, 2019

Learning Curve Exists for MitraClip, Volume-Outcomes Data Hint

News Conference News TCT 2019

Learning Curve Exists for MitraClip, Volume-Outcomes Data Hint

September 27, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

News Conference News TCT 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

September 25, 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

September 13, 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

News Conference News ESC 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

September 12, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

Community-Level Salt-Swapping Strategy Pays Dividends in Peru

News Conference News ESC 2019

Community-Level Salt-Swapping Strategy Pays Dividends in Peru

September 09, 2019

ESC Updates Guidance on Management of Acute Pulmonary Embolism

News Conference News ESC 2019

ESC Updates Guidance on Management of Acute Pulmonary Embolism

September 06, 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

News Conference News ESC 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

September 04, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

HiSTORIC Trial Supports Single-Test Rule-Out of MI Using High-Sensitivity Troponin

News Conference News ESC 2019

HiSTORIC Trial Supports Single-Test Rule-Out of MI Using High-Sensitivity Troponin

September 01, 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

September 01, 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

News Conference News ESC 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

August 31, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.